Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00380042 · ClinicalTrials.gov registry record · Phase 1
Assessment of the Safety and Effectiveness of Cortical Stimulation in Subjects With Major Depressive Disorder
A Phase 1 study, sponsored by Northstar Neuroscience.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00380042: Clinical Trial Phase 1 study, sponsored by Northstar Neuroscience.
NCT00380042 is a Phase 1 study that was terminated before completion, run by Northstar Neuroscience. The registered enrollment target is 12 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00380042, a Phase 1 study, was terminated before completion, sponsored by Northstar Neuroscience.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and effectiveness of cortical stimulation to the cerebral cortex of subjects who have suffered from treatment-resistant depression and have failed routine attempts at controlling their depression.
Interventions
- DEVICE Sham
- DEVICE Cortical Stimulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2006-09 |
| Est. Completion | 2009-03 |
| Phase | Phase 1 |
Why NCT00380042 stopped before completion
NCT00380042 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 2 interventions - of which Sham is the first listed.
NCT00380042 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00380042 about?
NCT00380042 is a clinical study titled "Assessment of the Safety and Effectiveness of Cortical Stimulation in Subjects With Major Depressive Disorder". The purpose of this study is to assess the safety and effectiveness of cortical stimulation to the cerebral cortex of subjects who have suffered from treatment-resistant depression and have failed routine attempts at controlling their depression.
What is the current status of trial NCT00380042?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2006-09. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00380042?
The interventions under investigation include: Sham (DEVICE), Cortical Stimulation (DEVICE).
Who is sponsoring clinical trial NCT00380042?
This trial is sponsored by Northstar Neuroscience, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00380042's enrollment target sits among peer trials
12 1852nd of 2000 higher than 90 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia